Patent classifications
A61K33/04
COMPOSITIONS FOR ORAL MICROADHESIVE DOSAGE FORMS
The present disclosure relates to the field of oral mucoadhesive dosage forms and the type and amounts of structural components to improve mucoadhesion. The present disclosure further relates to combinations of active ingredients within a mucoadhesive dosage form.
COMPOSITIONS FOR ORAL MICROADHESIVE DOSAGE FORMS
The present disclosure relates to the field of oral mucoadhesive dosage forms and the type and amounts of structural components to improve mucoadhesion. The present disclosure further relates to combinations of active ingredients within a mucoadhesive dosage form.
ULCERATIVE COLITIS DIET, FORMULAE, PRODUCTS AND METHODS THEREOF
An affordable, palatable, maintainable and clinically-useful UC diet, characterized by a low content of sulfur, heme animal-based protein, taurine, animal-saturated fat.
ULCERATIVE COLITIS DIET, FORMULAE, PRODUCTS AND METHODS THEREOF
An affordable, palatable, maintainable and clinically-useful UC diet, characterized by a low content of sulfur, heme animal-based protein, taurine, animal-saturated fat.
Pharmaceutical composition for use in the treatment of prostate pathologies
The present invention relates to a pharmaceutical composition for use in the treatment of prostate pathologies. The present invention further relates to a composition comprising a mixture which comprises or, alternatively, consists of an effective amount of Serenoa repens, Bromelain, Curcumin, Zinc, Lycopene and Selenium, and pharmaceutically acceptable or food grade technological excipients and/or additives. The present invention further relates to a pharmaceutical composition, preferably in the form of softgel capsules, for use in the treatment of disorders or diseases or pathologies connected to and/or deriving from prostatitis and/or benign prostatic hyperplasia.
Pharmaceutical composition for use in the treatment of prostate pathologies
The present invention relates to a pharmaceutical composition for use in the treatment of prostate pathologies. The present invention further relates to a composition comprising a mixture which comprises or, alternatively, consists of an effective amount of Serenoa repens, Bromelain, Curcumin, Zinc, Lycopene and Selenium, and pharmaceutically acceptable or food grade technological excipients and/or additives. The present invention further relates to a pharmaceutical composition, preferably in the form of softgel capsules, for use in the treatment of disorders or diseases or pathologies connected to and/or deriving from prostatitis and/or benign prostatic hyperplasia.
Pharmaceutical composition for use in the treatment of prostate pathologies
The present invention relates to a pharmaceutical composition for use in the treatment of prostate pathologies. The present invention further relates to a composition comprising a mixture which comprises or, alternatively, consists of an effective amount of Serenoa repens, Bromelain, Curcumin, Zinc, Lycopene and Selenium, and pharmaceutically acceptable or food grade technological excipients and/or additives. The present invention further relates to a pharmaceutical composition, preferably in the form of softgel capsules, for use in the treatment of disorders or diseases or pathologies connected to and/or deriving from prostatitis and/or benign prostatic hyperplasia.
Microdaily-Children gummy for optimal growth, development, and health
A formulation comprising at least on vitamin, at least one antioxidant, at least one mineral, at least one plant based nutrient and sodium.
Microdaily-Children gummy for optimal growth, development, and health
A formulation comprising at least on vitamin, at least one antioxidant, at least one mineral, at least one plant based nutrient and sodium.
Compositions and methods for the treatment of meibomian gland dysfunction
Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.